Sort   by:  
 Page size 
Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolomics analyses of patients' tumours, metastasis-derived patient-derived xenografts (PDX) and isogenic cell line...
2023-06-27 | MTBLS3342 | MetaboLights

PURPOSE: Detecting signals of micrometastatic disease in early breast cancer (EBC) patients could improve risk stratification and allow better tailoring of adjuvant therapies. We have previously shown that postoperative serum metabolomic profiles are predictive of relapse in a si...

2017-03-02 | MTBLS424 | MetaboLights

Breast cancer metastasis occurs via blood and lymphatic vessels. Breast cancer cells 'educate' lymphatic endothelial cells (LECs) to support tumor vascularization and growth. However, despite known metabolic alterations in breast cancer, it remains unclear how lymphatic endothelial cell metabolis...

2024-06-25 | MTBLS859 | MetaboLights

Lipid metabolism drives cancer progression but is difficult to model using conventional methods. In vivo models provide circulating lipids, but are costly and low throughput, while in vitro models lack sufficient lipid availability in culture media. Here, we evaluate the chick chorioallantoic mem...

2026-07-16 | MTBLS13377 | MetaboLights

Metastatic breast tumors must adapt to the metabolic constraints of their target tissues. To understand how tumor metabolism varies across sites, we compared glucose utilization in primary mammary fat pad (MFP) tumors and brain metastases derived from the breast cancer cell line MDA-MB-231. Tumor...

2025-12-30 | MTBLS13152 | MetaboLights

Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (Her2-) breast cancer (BC) patients, can be effectively targeted with the alpha isoform-specific PI3K inhibitor Alpelisib. This treatment significantly improves ...

2026-08-21 | MTBLS11671 | MetaboLights
Metastasis of breast cancer to other distant organs is fatal to patients. However, few studies have revealed biomarkers associated with distant metastatic breast cancer. Furthermore, the inability of current biomarkers such as HER2, ER and PR, in accurately differentiating between distant metastatic...
ORGANISM(S): Homo sapiens (Human) 
2020-06-05 | PXD016061 | Pride
19 non-metastatic breast cancers (controls) and 19 breast cancers showing metastases or metastatic relapse within 5 years (cases) were extracted from a multi-institutional case series of 123 breast cancer patients . Cases and controls were analyzed for DNA methylation over 56 genes by the MethDet as...
ORGANISM(S): Homo sapiens 
We identified 967 proteins among 75 serum samples from patients with BC. Among these, 39 proteins were altered in serum samples at diagnosis, between progressors and non-progressors. Among these, 4 proteins were further altered when the progressors developed distant metastasis. In addition, within p...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2024-03-07 | MSV000094255 | MassIVE
This is a genomic analysis of breast cancer metastasis using array based CGH and is part of a large study investigating the patterns and evolution of metastases from breast cancer using autopsy material accumulated over the last 50 years from a single institution. The samples used in the genomic pro...
ORGANISM(S): Homo sapiens 
Sort   by:  
 Page size